

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-20. (Canceled)

21. (Currently Amended) An isolated polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence corresponding to residues 163 to 199 of DP-1, said sequence being:

KNIRRRVYDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1); or

(ii) a sequence consisting of the amino acid sequence corresponding to residues 163-199 of DP-1, said sequence being:

KNIRRRVYDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1)[[,]] and ~~said sequence further including from~~ attached to 1 to 5 amino acid residues at the N- or C-terminus of SEQ ID NO:1 ~~thereof~~, where the presence of ~~such~~ said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide.

22. (Currently Amended) An isolated polypeptide consisting

of a ~~first~~ fragment of a sequence consisting of the amino acid sequence KNIRRRVYDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), and a ~~second fragment consisting of~~ from 1 to 5 amino acid residues joined to at least one of the N- or C-terminus of the ~~first~~ fragment, where the presence of the 1 to 5 amino acid residues ~~second fragment~~ has no significant effect on the function of the polypeptide;

which polypeptide is capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

23. (Currently Amended) The polypeptide according to claim 22 wherein said first-fragment ~~[[is]]~~consists of the amino acid sequence NVLMAMNII (SEQ ID NO:2) or ALNVLMA (SEQ ID NO:7).

24. (Currently Amended) The polypeptide according to claim 22 wherein said first-fragment ~~[[is]]~~ consists of an amino acid sequence selected from the group consisting of:

RRRVYDALNVLMAMNIISK (SEQ ID NO:3);

NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4);

RVYDALNVLMAMNIIS (SEQ ID NO:5); and

YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6).

25. (Currently Amended) An isolated variant of a polypeptide consisting of:
(i) a sequence consisting of the amino acid sequence ~~corresponding to residues 163 to 199 of DP-1, said sequence being:~~

KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

(ii) a sequence consisting of the amino acid sequence ~~a sequence corresponding to residues 163 to 199 of DP-1, said sequence being:~~
KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), ~~and said sequence further including from~~ attached to 1 to 5 amino acid residues at the N- or C-

terminus of SEQ ID NO:1 thereof, where the presence of said 1 to 5 amino acid such residues has no significant effect on the function of the polypeptide;

said variant differing from the polypeptide by the presence of from 1 to 5 amino acid substitutions in the sequence of said polypeptide, said variant being capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

26. (Previously Presented) The variant according to claim 25 wherein the substitutions include substitutions selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

27. (Currently Amended) An isolated polypeptide consisting of an amino acid sequence (i) attached to an amino acid sequence (ii) wherein said amino acid sequence (ii) is attached to the N- or C- terminus of said amino acid sequence (i),

said amino acid sequence (i) consisting of ~~which consists of:~~

~~(i) a first portion having~~ an amino acid sequence selected from the group consisting of:

- (a) KNIRRRVYDALNVLAMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),
- (b) NVLAMAMNII (SEQ ID NO:2),
- (c) RRRVYDALNVLAMAMNIISK (SEQ ID NO:3),
- (d) NVLAMAMNIISKEKKEIKWIG (SEQ ID NO:4),
- (e) RVYDALNVLAMAMNIIS (SEQ ID NO:5),
- (f) YDALNVLAMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6), and
- (g) ALNVLMA (SEQ ID NO:7); and

said amino acid sequence (ii) consisting of a second portion, attached to the N- or C-terminus of the first portion, which consists of a sequence of amino acids not naturally contiguous to said amino sequence (i)~~the first portion in DP-1.~~

28. (Currently Amended) A polypeptide according to claim 27 wherein the amino acid sequence (ii) second portion is a membrane translocation sequence.

29. (Previously Presented) A polypeptide according to claim 28 wherein the membrane translocation sequence is a membrane translocation sequence of the *Drosophila melanogaster antennapedia* protein.

30. (Previously Presented) A composition comprising a polypeptide according to any one of claims 21 to 29 together with a pharmaceutically acceptable diluent or carrier.

31. (Previously Presented) A composition according to claim 30 which further comprises a cytostatic or cytotoxic agent.

32. (Previously Presented) A composition formulation comprising a polypeptide of SEQ ID NO:1 in the form of an orally, topically or parenterally administrable form.

33. (Withdrawn) A method of inducing apoptosis in a cell which comprises introducing into said cell an effective amount of a polypeptide according to claim 21.

34. (Withdrawn) A method according to claim 33 wherein said cell is a tumour cell.

35. (Withdrawn) A method according to claim 33 wherein said cell is a cardiovascular cell.

36. (Currently Amended) An isolated product comprising a polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence corresponding to residues 163 to 199 of DP-1, said sequence being:

KNIRRRVYDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

(ii) a sequence consisting of the amino acid sequence corresponding to residues 163 to 199 of DP-1, said sequence being:

KNIRRRVYDALNVLAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), ~~and said sequence further including from~~ attached to 1 to 5 amino acid residues at the N- or C-terminus ~~of SEQ ID NO:1 thereof~~, where the presence of the 1 to 5 amino acids such residues has no significant effect on the function of the polypeptide;

and a cytostatic or cytotoxic agent as a combined preparation.

37. (Withdrawn) A method of treating uncontrolled proliferation of cells in a human or animal body in need of said treating comprising administering a composition of claim 31 to said human or animal body such that said uncontrolled proliferation of cells is treated.